Fiserv earnings missed by $0.61, revenue fell short of estimates
Investing.com - H.C. Wainwright has reiterated a Buy rating on Gain Therapeutics (NASDAQ:GANX) with an $8.00 price target following a virtual key opinion leader event hosted by the company. According to InvestingPro data, analysts maintain a strong Buy consensus with targets ranging from $6 to $12, suggesting significant upside potential from the current $1.81 price level.
The event, titled "Biomarkers, Clinical Endpoints, and the Path to Disease Modification: Contextualizing the emerging data from GT-02287," featured experts Karl Kieburtz, M.D., M.P.H., Professor of Neurology at the University of Rochester, and Kenneth Marek, M.D., President and Senior Scientist at the Institute for Neurodegenerative Disorders.
The discussion centered on GT-02287’s mechanism of action in relation to Parkinson’s disease pathophysiology and its potential therapeutic impact. Key opinion leaders expressed positive views toward the compound, noting its differentiated approach to stabilizing and enhancing glucocerebrosidase function.
Experts specifically highlighted that GT-02287 could be used alongside existing Parkinson’s treatments such as levodopa/carbidopa and COMT inhibitors. They also noted the "unusual" rapid improvement seen in Movement Disorder Society Unified Parkinson’s Disease Rating Scale scores after only 90 days in the Phase 1b trial.
The key opinion leaders additionally discussed the possibility of improvement in Parkinson’s symptoms with longer-term studies assessing the compound over six to twelve months.
In other recent news, Gain Therapeutics has reported encouraging preliminary results from its Phase 1b clinical study of GT-02287, a treatment for Parkinson’s disease. The company announced that after 90 days of dosing, the drug was generally well tolerated with no serious adverse events, despite some participants experiencing temporary increases in liver enzymes. Interim data presented at the International Congress of Parkinson’s Disease and Movement Disorders showed improvements in a standard measure of Parkinson’s severity among the first nine participants. Gain Therapeutics also announced a nine-month extension of the study, with most of the 21 participants opting to continue treatment beyond the initial period. Approval from Australian ethics committees has allowed the extension of the trial to 12 months, with many participants expressing interest in continuing. H.C. Wainwright has reiterated its Buy rating and set a price target of $8.00 on Gain Therapeutics, maintaining a positive outlook on the company. The Phase 1b study reached its original enrollment target ahead of schedule and continued to accept pre-screened candidates through the end of July. These developments reflect ongoing progress in Gain Therapeutics’ clinical efforts.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.